Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Syndax Pharmaceuticals (SNDX) EBIAT (2016 - 2020)

Syndax Pharmaceuticals has reported EBIAT over the past 6 years, most recently at -$20.4 million for Q4 2020.

  • Quarterly results put EBIAT at -$20.4 million for Q4 2020, down 45.88% from a year ago — trailing twelve months through Dec 2020 was -$73.2 million (down 30.53% YoY), and the annual figure for FY2025 was -$285.4 million, up 10.46%.
  • EBIAT for Q4 2020 was -$20.4 million at Syndax Pharmaceuticals, roughly flat from -$20.4 million in the prior quarter.
  • Over the last five years, EBIAT for SNDX hit a ceiling of -$8.4 million in Q2 2016 and a floor of -$20.4 million in Q3 2020.
  • Median EBIAT over the past 5 years was -$15.0 million (2016), compared with a mean of -$15.4 million.
  • Biggest five-year swings in EBIAT: tumbled 110.34% in 2016 and later increased 26.27% in 2019.
  • Syndax Pharmaceuticals' EBIAT stood at -$10.8 million in 2016, then plummeted by 76.64% to -$19.1 million in 2017, then increased by 1.4% to -$18.8 million in 2018, then rose by 25.68% to -$14.0 million in 2019, then crashed by 45.88% to -$20.4 million in 2020.
  • The last three reported values for EBIAT were -$20.4 million (Q4 2020), -$20.4 million (Q3 2020), and -$17.1 million (Q2 2020) per Business Quant data.